Key result
Candesartan and perindopril significantly prevented free fatty acid-induced decreases in myocardial capillary blood velocity and myocardial blood flow during hyperemia.
Why the study?
Do renin-angiotensin system inhibitors (candesartan or perindopril) prevent intravenous lipid infusion-induced myocardial microvascular dysfunction and leukocyte activation in healthy men?
RCT (n=18)
Double-blind
Randomized
No
Do renin-angiotensin system inhibitors (candesartan or perindopril) prevent intravenous lipid infusion-induced myocardial microvascular dysfunction and leukocyte activation in healthy men?
p-value: p=<0.05
Short-term administration of renin-angiotensin system inhibitors prevents acute lipid-induced myocardial microvascular dysfunction and leukocyte activation, providing mechanistic insight into their vascular protective effects.
RAS inhibitors prevent FFA-induced myocardial microvascular dysfunction; extends mechanistic evidence to hyperemia in humans.
BACKGROUND: Levels of triglycerides and free fatty acids (FFAs) are elevated in patients with diabetes and may contribute to endothelial dysfunction through renin-angiotensin system (RAS) activation and oxidative stress. The present study investigated how systemic FFA loading affected myocardial microcirculation during hyperemia via RAS. METHODS AND RESULTS: Eight healthy men received candesartan, perindopril, or a placebo for 2 days in a double-blind crossover design, and then myocardial microcirculation during hyperemia induced by a 2-h infusion of lipid/heparin was assessed using dipyridamole stress-myocardial contrast echocardiography (MCE). Leukocyte activity and hemorheology were also assessed ex vivo using a microchannel flow analyzer, serum levels of oxidative stress markers, and IκB-α expression in mononuclear cells. Serum FFA elevation by the infusion of lipid/heparin significantly decreased myocardial capillary blood velocity and myocardial blood flow during hyperemia. Both candesartan and perindopril significantly prevented the FFA-induced decrease in capillary blood velocity and myocardial blood flow during hyperemia. Systemic FFA loading also caused an increase in the number of adherent leukocytes and prolonged the whole blood passage time. These effects were blocked completely by candesartan and partially by perindopril. Both agents prevented the FFA-induced enhancement of oxidative stress and IκB-α degradation in mononuclear cells. CONCLUSIONS: Both candesartan and perindopril can prevent FFA-induced myocardial microcirculatory dysfunction during hyperemia via modulation of leukocyte activation and microvascular endothelial function.
No takes yet. Share an insight, caveat, or question.
Yasu et al. (2017) conducted an RCT in Healthy volunteers (n=18). Candesartan or Perindopril vs. Placebo was evaluated on Myocardial capillary blood velocity and myocardial blood flow during hyperemia (p=<0.05). Candesartan and perindopril significantly prevented free fatty acid-induced decreases in myocardial capillary blood velocity and myocardial blood flow during hyperemia.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: